Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban

Journal of Extra-Corporeal Technology

Volumn 38, Issue 3, 2006, Pages 230-234

  Meola, Stacy ^a,b   Burns, Gregory ^a,b   Sukavaneshvar, Sivaprasad ^b,c   Solen, Kenneth ^d   Mohammad, Syed ^a,b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Utah Artificial Heart Institute   (United States)

^c Medical Device Evaluation Center   (United States)

^d Department of Electrical and Computer Engineering   (United States)

Author keywords

Anti platelet; Anticoagulant; Platelets; Stent; Thromboembolism

Indexed keywords

ANTITHROMBOCYTIC AGENT; HEPARIN; NITINOL; TIROFIBAN; ANTICOAGULANT AGENT; DRUG DERIVATIVE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DEVICE; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; LIGHT SCATTERING; MALE; MICROEMBOLISM; NONHUMAN; SHEEP; SHUNT THROMBOSIS; THROMBOEMBOLISM; THROMBOSIS; ANIMAL; DRUG COMBINATION; IN VITRO STUDY; STENT;

ANIMALS; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; HEPARIN; MALE; PLATELET AGGREGATION INHIBITORS; SHEEP; STENTS; THROMBOEMBOLISM; THROMBOSIS; TYROSINE;

EID: 39049191889     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hilt T, Bayat M. Drugs used to limit blood surface interactions. Crit Care Nurs Clin North Am. 2002;14:7-16.
2. Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: Basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am. 2005;19:1-51.
3. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25:5681-703.
4. Poncz M. Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg. 2005;17:73-9.
5. Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res. 2003;15:355-9.
6. Tamberella MR, Furman MI. The role of platelet inhibition in the drug-eluting stent era. Coron Artery Dis. 2004;15:327-9.
7. Koster A, Fischer T, Gruendel M, et al. Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth. 2003;17:171-5.
8. Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14:2313-21.
9. Sukavaneshvar S, Zheng Y, Rosa GM, Mohammad SF, Solen KA. Thromboembolization associated with sudden increases in flow in a coronary stent ex vivo shunt model. ASAIO J. 2000;46:301-4.
10. Solen K, Sukavaneshvar S, Zheng Y, et al. Light-scattering instrument to detect thromboemboli in blood. J Biomed Opt. 2003;8:70-9.
11. Sukavaneshvar S, Solen KA, Mohammad SF. An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of Tirofiban, aspirin, and dipyridamole. Thromb Haemost. 2000;83:322-6.
12. Nollert G, Reichart B. Cardiopulmonary bypass and cerebral injury in adults. Shock. 2001;16(Suppl 1):16-9.
13. Raymond PD, Marsh NA. Alterations to haemostasis following cardiopulmonary bypass and the relationship of these changes to neurocognitive morbidity. Blood Coagul Fibrinolysis. 2001;12:601-18.
14. Mezzano D, Tagle R, Panes O, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost. 1996;76:312-21.
15. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-7.